Form 4: Stoke Therapeutics CFO Stephen Tulipano Reports Stock Transactions
SEC Form 4 Filing
Stephen Tulipano, CFO of Stoke Therapeutics, reports acquisition and disposal of common stock and restricted stock units.
Summary
- On March 15, 2024, Stephen Tulipano, CFO of Stoke Therapeutics, acquired 13,100 shares of common stock at $0 and disposed of 4,116 shares on March 19, 2024, at a weighted average price of $6.0986.
- These transactions were related to the vesting and settlement of restricted stock units (RSUs).
- Following these transactions, Tulipano beneficially owns 20,746 shares of common stock.
- The acquisition of 13,100 restricted stock units (RSUs) occurred on March 15, 2024, vesting annually beginning on the same date, subject to continued service.
Sentiment
Score: 5
Explanation: The document is a standard regulatory filing detailing stock transactions. It doesn't convey any specific positive or negative sentiment about the company's performance or outlook.
Industry Context
This Form 4 filing is a routine disclosure of stock transactions by a company insider, as required by the SEC. It provides transparency into the trading activities of key personnel and their holdings in the company.
Key Dates
| Date | Description |
|---|---|
| 03/15/2024 | Acquisition of 13,100 shares of common stock and vesting of restricted stock units. |
| 03/15/2027 | Expiration date of restricted stock units. |
| 03/19/2024 | Disposal of 4,116 shares of common stock. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.